Shape Biopharmaceuticals AG
Shape Biopharmaceuticals is advancing a first-in-class, ultra-low-dose, long-acting, multi-target antibody-inducing immunotherapy platform that programs the immune system to address key drivers of cardiometabolic disease. It enables durable, multi-pathway modulation of lipid biology, reducing residual cardiovascular risk beyond current therapies, with robust in vivo LDL-C and triglyceride lowering. The platform offers expansion potential across multi-target opportunities.
Date, time and room information
Tuesday, May 5, 14:15 - 14:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Programming Immunity for Cardiometabolic Disease
Speaker information
| Name | Position | Institution |
|---|---|---|
| Arin Ghasparian | CEO |
Host and event manager:
Logistics and marketing partner:
